AbbVie’s blockbuster drug Humira finally loses its 20-year, $200 billion monopoly

Humira, the injectable biologic treatment for rheumatoid arthritis, now faces its first competition from one of several copycat "biosimilar" drugs expected to come to market this year. Some patients spend $70,000 a year on Humira.

U.S. doctors can now choose Amjevita instead, the first of several close copies of the popular rheumatoid arthritis drug expected this year. But industry-watchers warn consumer savings may be limited.

(Image credit: JB Reed/Bloomberg via Getty Images)

Read the full post on Health Care : NPR

Leslie Walker